Status:
COMPLETED
Comparing Different Methods for Collection of Comorbidity Data Per the HCT-CI
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Hematopoietic Malignancy
Eligibility:
All Genders
20+ years
Brief Summary
Comorbidity assessment in the field of HCT might be a burden on the medical team at the clinic or the research staff. This research study aims to explore and validate new methods, Claims-based and pat...
Detailed Description
Studies have shown the importance of pre-transplant comorbidities in predicting mortality after allogeneic HCT. However, comorbidity assessment might be a burden on the medical team at the clinic or ...
Eligibility Criteria
Inclusion
- Patients eligible for autologous or allogeneic HCT.
- Able to speak and read English.
- Willing and able to provide informed consent.
- There is no restriction based on diagnosis, intensity of conditioning regimen, type of donor graft, degree of HLA-matching, or stem cell source.
- Patients \>20 years old
- Access to a telephone for study-related communications.
Exclusion
- HCT candidates who cannot read, write, or speak English.
- Patients \<20 years old
Key Trial Info
Start Date :
March 22 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT03434561
Start Date
March 22 2013
End Date
June 1 2016
Last Update
May 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109